AVN-211
id:
avn-211-239-13861845
title:
AVN-211
text:
AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia. In early 2011, it successfully completed phase IIa clinical trials, with benefits on positive symptoms and some procognitive effects observed, and in mid 2013, phase IIb clinical trials for schizophrenia began. Avineuro Pharmaceuticals also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/AVN-211
date created:
date modified:
2023-12-24T13:24:14Z
main entity:
{"identifier":"Q19596009","url":"https://www.wikidata.org/entity/Q19596009"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/3/39/AVN-211_Structure.svg","width":4351,"height":5124}
fields total:
13
integrity:
15